Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.

Targeted agents such as bevacizumab (BEV) or poly (ADP-ribose) polymerase inhibitors (PARPi) which have been added as concomitant or maintenance therapies have been shown to improve progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer (PS rOC). In the absence of direct comparison, we performed a network meta-analysis considering We searched PubMed, EMBASE, and MEDLINE for trials involving patients with PS rOC treated with BEV or PARPi. Different comparisons were performed for patients included in the PARPi trials, according to In the overall population, PARPi prolonged PFS with respect to BEV (hazard ratio (HR) = 0.70, 95% CI 0.54-0.91). In the PARPi performed better as compared with BEV in terms of PFS for the treatment of PS rOC, especially in BRCAm patients who had not previously received PARPi.

Déclaration de conflit d'intérêts

F.P. reports grants from AstraZeneca; grants, personal fees, and other from Roche; personal fees and other from Eli Lilly; personal fees from Amgen; personal fees from Ipsen; personal fees from MSD; personal fees from Takeda; grants and other from Eisai; other from Novartis and Pfizer, outside the submitted work. L.G. reports personal fees from Eli lilly, outside the submitted work. The other authors have nothing to disclose.